Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Xtandi (enzalutamide) Disease area(s): Oncology Manufacturer(s): Astellas/Pfizer 2024 Sales (USD): $7.94 billion Why it sold so well: In 2024, Astellas Pharmas Xtandi, co-marketed with Pfizer, posted strong sales growth, with revenues reaching 703.1 billion ($4.64 billion) for the first nine months (April 1, 2024 to December 31, 2024), marking a 25.6% increase compared to the same period in the previous year
Metabolism 9, 147157
Ready to verify and browse
pharmacies set their own prices
Less significant pathogen-induced enzyme activity changes were detected in Mla -type resistant plants that showed HR-type cell death following inoculation, and, to an even lesser extent, in Mlg and mlo lines with no visible symptoms accompanying the incompatible interaction (Harrach et al., 2008)
Ro includes weekly coaching
